ENDRA Life Sciences (NASDAQ:NDRA) Announces Quarterly Earnings Results, Beats Expectations By $0.21 EPS

ENDRA Life Sciences (NASDAQ:NDRA) announced its quarterly earnings data on Friday. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.21, Zacks reports.

ENDRA Life Sciences Stock Performance

Shares of NASDAQ NDRA remained flat at $4.47 during midday trading on Friday. 51,812 shares of the stock traded hands, compared to its average volume of 16,716. ENDRA Life Sciences has a 1-year low of $2.96 and a 1-year high of $9.85. The business has a fifty day simple moving average of $4.85 and a two-hundred day simple moving average of $4.60.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Weiss Ratings upgraded ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. Ascendiant Capital Markets dropped their price target on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $25.00.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.